C2 Pharma launches initiative to bring a reliable source of naturally extracted GMP-compliant Cannabidiol (CBD) to pharmaceutical companies
C2 Pharma has announced a major expansion of its R&D programme to grow its API portfolio at CPhI 2018 in Madrid (Hall 6, Booth 6F40).
The R&D programme covers synthetic APIs as well as naturally extracted APIs and botanicals for pharmaceutical use.
APIs under development:
APIs in feasibility stage:
Botanical extracts under development:
C2 Pharma is also launching a major initiative to bring a reliable source of naturally extracted GMP-compliant cannabidiol (CBD) to the pharma industry. The cultivation of cannabis will be fully compliant with Good Agricultural Practices (GAP) and follow a rigorous framework established and tested by C2 Pharma to manage its partner-growers.
The extraction and manufacturing of pure Cannabidiol (CBD) will be based within the European Union and will use the latest purification techniques. Samples will be available in first quarter of 2019, with commercial GMP quantities planned for the fourth quarter of 2019.
In parallel, C2 Pharma is working on additional collaborations in the field of cultivation, manufacturing and extraction technology as well as analytical methods to meet the specific needs of the burgeoning cannabis industry as a medicinal product in Europe and globally. Additional announcements are expected in November 2018.
“We are taking the lead to develop the API and botanical extract solutions the pharmaceutical industry will need to enable it to bring Cannabidiol (CBD) into an incredibly broad range of therapeutic applications. Our involvement as a specialist API manufacturer will provide pharmaceutical companies with the credibility and reliability they need to run their programs,” said Andrew Badrot, CEO of C2 Pharma.
“Whether you are exploring the entourage effect of cannabis extracts or need the pure API, we will have a solution for you.”